A Phase 2 Randomized, Double-Blind, Placebo-controlled Trial of Oral Camostat Mesylate for Early Treatment of COVID-19 Outpatients Showed Shorter Illness Course and Attenuation of Loss of Smell and Taste

IMPORTANCE: Early treatment of mild SARS-CoV-2 infection might lower the risk of clinical deterioration in COVID-19. OBJECTIVE: To determine whether oral camostat mesylate would reduce upper respiratory SARS-CoV-2 viral load in newly diagnosed outpatients with mild COVID-19, and would lead to improv...

Descripción completa

Detalles Bibliográficos
Autores principales: Chupp, Geoffrey, Spichler-Moffarah, Anne, Søgaard, Ole S., Esserman, Denise, Dziura, James, Danzig, Lisa, Chaurasia, Reetika, Patra, Kailash P., Salovey, Aryeh, Nunez, Angela, May, Jeanine, Astorino, Lauren, Patel, Amisha, Halene, Stephanie, Wang, Jianhui, Hui, Pei, Patel, Prashant, Lu, Jing, Li, Fangyong, Gan, Geliang, Parziale, Stephen, Katsovich, Lily, Desir, Gary V., Vinetz, Joseph M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820673/
https://www.ncbi.nlm.nih.gov/pubmed/35132421
http://dx.doi.org/10.1101/2022.01.28.22270035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820673/
https://www.ncbi.nlm.nih.gov/pubmed/35132421
http://dx.doi.org/10.1101/2022.01.28.22270035

Ejemplares similares